Anti Inflammatory News and Research

RSS

White tea, witch hazel and rose have potential health and beauty properties

Age-old remedies could hold the key to treating a wide range of serious medical problems, as well as keeping skin firmer and less wrinkled, according to scientists from London's Kingston University.

2 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

MRG releases 2012 report on US markets for ENT and bronchoscopy devices

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, advances in procedures competing with functional endoscopic sinus surgery (FESS) and nasal packing devices will have a significant positive effect on the ear, nose and throat (ENT) device market in the United States over the next few years.

From Evident Corporation - Life Sciences 28 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Study examines how mice with genetic bone defects respond to infusions of BMMSC

A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.

21 Nov 2011

Omega-3 linked with reduced joint pain and cognitive side effects of breast cancer therapy

"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."

19 Nov 2011

Dipyrone may reduce brain damage after stroke

An older nonsteroidal anti-inflammatory drug (NSAID) called dipyrone may offer a new approach to reducing injury to brain tissue after a stroke, according to a study in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Nov 2011

Cyanotech second quarter revenues increase to $5,989,000

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the second quarter and first six months of fiscal year 2012, ended September 30, 2011.

14 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Inflammatory arthritis or autoimmune disease ruled out as cause for joint pain associated with AIs

Researchers exploring why some women who take a common breast cancer drug develop serious joint pain have eliminated two possible causes: inflammatory arthritis and autoimmune disease.

11 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

N-acetylcysteine plus cortisone shows promise against acute alcoholic hepatitis

Acute alcoholic hepatitis is one of the most serious forms of alcoholic liver disease, affecting individuals with chronic excessive alcohol consumption, which generally equates to more than 50 grams of alcohol per day, over a period of more than three to six months. The disease is characterized by liver failure and acute jaundice (icterus), which may induce a coma through liver failure and an ensuing death rate of between 40-45% within the first six months.

11 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

$Narcotic analgesics increase risk of falls and fractures among elderly$

Narcotic analgesics increase risk of falls and fractures among elderly

Falls and fractures among senior citizens have increased since rofecoxib was removed from the market in 2004, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Taking methotrexate or anti-TNFs is associated with a reduction in risk of cardiovascular disease in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

$New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout$

New data from Savient's KRYSTEXXA Phase III trial on refractory chronic gout

Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.

7 Nov 2011